CTLA4 and colitis: In contrast, only 11% (95% CI 7–15%) had colitis when receiving combination therapy with PD-1/PD-L1 and CTLA-4, of which only 15% (95% CI 8–22%) were of a more severe grade (grade 3–5) [53].